METOLAZONE Drug Patent Profile
✉ Email this page to a colleague
When do Metolazone patents expire, and when can generic versions of Metolazone launch?
Metolazone is a drug marketed by Alembic, Ani Pharms, Bayshore Pharms Llc, Innogenix, Mylan, Ne Rx Pharma, Renata, Roxane, Rubicon, Sandoz, and Watson Labs. and is included in twelve NDAs.
The generic ingredient in METOLAZONE is metolazone. There are ten drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the metolazone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Metolazone
A generic version of METOLAZONE was approved as metolazone by SANDOZ on December 19th, 2003.
Summary for METOLAZONE
US Patents: | 0 |
Applicants: | 11 |
NDAs: | 12 |
Finished Product Suppliers / Packagers: | 17 |
Raw Ingredient (Bulk) Api Vendors: | 86 |
Clinical Trials: | 22 |
Patent Applications: | 5,056 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for METOLAZONE |
Drug Sales Revenues: | Drug sales revenues for METOLAZONE |
What excipients (inactive ingredients) are in METOLAZONE? | METOLAZONE excipients list |
DailyMed Link: | METOLAZONE at DailyMed |
Recent Clinical Trials for METOLAZONE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Rambam Health Care Campus | Phase 4 |
St George's, University of London | Phase 3 |
NHS Greater Glasgow and Clyde | Phase 3 |
Pharmacology for METOLAZONE
Drug Class | Thiazide-like Diuretic |
Physiological Effect | Increased Diuresis |